OIl Tech Flickr Courtesy: epSos.de / Flickr
29 October 2015

How technology can cap oil prices

Developments in electric vehicles, battery technology, and renewable energy can make oil, coal, nuclear power interchangeable, if the appropriate technology is developed and marketed well.  And since the benefits include a permanent cap on energy prices, India must promote  its own industries in these areas and not remain a passive beneficiary.

hqdefault Courtesy:
22 October 2015

T20 Opening Statement by Dr. Burak Akçapar, Ambassador of Turkey to India

Turkey's Ambassador to India Dr. Burak Akçapar's opening statement for T20 Mumbai was about the progress of the G20 under Turkey's presidency and G20's growing responsibility to the world. An abridged version of this speech was delivered by Erdal Sabri Ergen at the T20 Mumbai regional consultation meeting on 19 October

Modi Obama Wiki Courtesy: Wikipedia
21 October 2015

Building on India-U.S. meeting points

Modi’s second visit to the U.S. in September indicates a growing partnership in such areas as business, technology, and climate change. Though gaps too remain—for example, India is not part of the TPP and its bid for a UNSC seat is on hold—for now, it is time to consolidate bilateral meeting points, and India can start by simplifying its trade policy and tariff structure

NPH_8640 Courtesy: Gateway House
21 October 2015

T20 Mumbai Keynote by Dr. Rajan

Dr. Raghuram Rajan, Governor, Reserve Bank of India, delivered the keynote address at India's first Think20 (T20) meeting organised by Gateway House with TEPAV, on the "Global Economy and Challenges for Multilateral Policies." He urged emerging markets like India to develop their own capacity to provide new ideas to the global financial system, “hold the pen” that will write a more inclusive agenda, and strengthen global multilateral institutions.

Pharma Pixelbay Courtesy: Pixabay
21 October 2015

Will the TPP impact Indian pharma?

Do the TPP and the proposed India-EU trade deal extend protection of IPR, delaying generic competition for life-saving drugs and keeping their prices high? While these and other possible implications for Indian consumers and pharma companies become clearer over time, India must robustly engage with the debate on trade deals and public interest